JOUNCE THERAPEUTICS INC (JNCE) Fundamental Analysis & Valuation

NASDAQ:JNCE • US4811161011

Current stock price

1.88 USD
-0.05 (-2.59%)
At close:
1.92 USD
+0.04 (+2.13%)
After Hours:

This JNCE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. JNCE Profitability Analysis

1.1 Basic Checks

  • JNCE had negative earnings in the past year.
  • In the past year JNCE has reported a negative cash flow from operations.
JNCE Yearly Net Income VS EBIT VS OCF VS FCFJNCE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M -100M 150M

1.2 Ratios

  • JNCE has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JNCE Yearly ROA, ROE, ROICJNCE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 20 -20 -40

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for JNCE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JNCE Yearly Profit, Operating, Gross MarginsJNCE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. JNCE Health Analysis

2.1 Basic Checks

  • JNCE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for JNCE has been increased compared to 1 year ago.
  • There is no outstanding debt for JNCE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
JNCE Yearly Shares OutstandingJNCE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
JNCE Yearly Total Debt VS Total AssetsJNCE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of 0.64, we must say that JNCE is in the distress zone and has some risk of bankruptcy.
  • JNCE's Altman-Z score of 0.64 is fine compared to the rest of the industry. JNCE outperforms 60.92% of its industry peers.
  • JNCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.64
ROIC/WACCN/A
WACC8.03%
JNCE Yearly LT Debt VS Equity VS FCFJNCE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 8.37 indicates that JNCE has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 8.37, JNCE is in the better half of the industry, outperforming 68.35% of the companies in the same industry.
  • JNCE has a Quick Ratio of 8.37. This indicates that JNCE is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of JNCE (8.37) is better than 68.35% of its industry peers.
Industry RankSector Rank
Current Ratio 8.37
Quick Ratio 8.37
JNCE Yearly Current Assets VS Current LiabilitesJNCE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. JNCE Growth Analysis

3.1 Past

  • JNCE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.20%, which is quite impressive.
  • Looking at the last year, JNCE shows a very strong growth in Revenue. The Revenue has grown by 205.20%.
  • JNCE shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.75% yearly.
EPS 1Y (TTM)46.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%266.1%
Revenue 1Y (TTM)205.2%
Revenue growth 3Y-17.85%
Revenue growth 5Y2.75%
Sales Q2Q%N/A

3.2 Future

  • JNCE is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.92% yearly.
  • JNCE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 48.27% yearly.
EPS Next Y-37.55%
EPS Next 2Y-3.02%
EPS Next 3Y-8.36%
EPS Next 5Y6.92%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y36.37%
Revenue Next 5Y48.27%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JNCE Yearly Revenue VS EstimatesJNCE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
JNCE Yearly EPS VS EstimatesJNCE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. JNCE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for JNCE. In the last year negative earnings were reported.
  • Also next year JNCE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JNCE Price Earnings VS Forward Price EarningsJNCE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JNCE Per share dataJNCE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • JNCE's earnings are expected to decrease with -8.36% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.02%
EPS Next 3Y-8.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. JNCE Dividend Analysis

5.1 Amount

  • JNCE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

JNCE Fundamentals: All Metrics, Ratios and Statistics

JOUNCE THERAPEUTICS INC

NASDAQ:JNCE (5/3/2023, 8:26:07 PM)

After market: 1.92 +0.04 (+2.13%)

1.88

-0.05 (-2.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-10
Earnings (Next)08-02
Inst Owners0%
Inst Owner Change0%
Ins Owners21.72%
Ins Owner Change0%
Market Cap98.95M
Revenue(TTM)82.00M
Net Income(TTM)-50.92M
Analysts80
Price Target1.65 (-12.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)901.63%
Min EPS beat(2)7.85%
Max EPS beat(2)1795.4%
EPS beat(4)3
Avg EPS beat(4)446.56%
Min EPS beat(4)-22.76%
Max EPS beat(4)1795.4%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)96.08%
Min Revenue beat(2)96.08%
Max Revenue beat(2)96.08%
Revenue beat(4)1
Avg Revenue beat(4)-34.64%
Min Revenue beat(4)-100%
Max Revenue beat(4)96.08%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-73.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-17.15%
EPS NY rev (1m)28.8%
EPS NY rev (3m)38.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.21
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.54
EV/EBITDA N/A
EPS(TTM)-0.99
EYN/A
EPS(NY)-1.36
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS1.56
BVpS3.48
TBVpS3.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.03%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.37
Quick Ratio 8.37
Altman-Z 0.64
F-Score3
WACC8.03%
ROIC/WACCN/A
Cap/Depr(3y)20.06%
Cap/Depr(5y)24.53%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%266.1%
EPS Next Y-37.55%
EPS Next 2Y-3.02%
EPS Next 3Y-8.36%
EPS Next 5Y6.92%
Revenue 1Y (TTM)205.2%
Revenue growth 3Y-17.85%
Revenue growth 5Y2.75%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y36.37%
Revenue Next 5Y48.27%
EBIT growth 1Y42.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.41%
OCF growth 3YN/A
OCF growth 5YN/A

JOUNCE THERAPEUTICS INC / JNCE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of JOUNCE THERAPEUTICS INC (JNCE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to JNCE.


What is the valuation status of JOUNCE THERAPEUTICS INC (JNCE) stock?

ChartMill assigns a valuation rating of 3 / 10 to JOUNCE THERAPEUTICS INC (JNCE). This can be considered as Overvalued.


What is the profitability of JNCE stock?

JOUNCE THERAPEUTICS INC (JNCE) has a profitability rating of 1 / 10.


What is the expected EPS growth for JOUNCE THERAPEUTICS INC (JNCE) stock?

The Earnings per Share (EPS) of JOUNCE THERAPEUTICS INC (JNCE) is expected to decline by -37.55% in the next year.